COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Ortonne, J. P. [1 ]
Feneron, D. [2 ]
Daures, J. P. [3 ]
Ollivier, A. L. [4 ]
Thiriet, C. [4 ]
Maurel, F. [2 ]
Le Pen, C. [5 ]
机构：
[1] Hop Archet 2, Nice, France
[2] IMS Hlth, Puteaux La Defense, France
[3] CHU Nimes, Nimes, France
[4] Wyeth Pharmaceut, Paris, France
[5] Univ Paris 09, Paris, France
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67017-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of the treatment for moderate to severe psoriasis in Mexico:: Infliximab, etanercept and efalizumab
    Mucino, E.
    Rivas, R.
    Zapata, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A288 - A288
  • [2] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [3] Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
    Hendrix, Nathaniel
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Loos, Anne
    Liu, Shanshan
    Kumar, Varun
    Linder, Jeffrey A.
    Pearson, Steven D.
    Veenstra, David L.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1210 - +
  • [4] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [5] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [6] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [7] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    [J]. VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [8] MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US
    Verma, S.
    Dharmarajan, S.
    Yang, Y.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [9] Efalizumab for the treatment of moderate to severe plaque psoriasis
    Jordan, JK
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1476 - 1482
  • [10] COST-EFFECTIVENESS OF USTEKINUMAB VERSUS ETANERCEPT IN SEVERE PLAQUE PSORIASIS PATIENTS: A CANADIAN PERSPECTIVE
    Brazier, N.
    Pan, F.
    Shear, N.
    Jivraj, F.
    Schenkel, B.
    Brown, R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
12345